130 related articles for article (PubMed ID: 7814879)
21. Induction of cytotoxic T lymphocytes from the peripheral blood of a hepatocellular carcinoma patient using melanoma antigen-1 (MAGE-1) peptide.
Lu J; Leng X; Peng J; Mou D; Pang X; Shang X; Chen W
Chin Med J (Engl); 2002 Jul; 115(7):1002-5. PubMed ID: 12150730
[TBL] [Abstract][Full Text] [Related]
22. [The genetic polymorphism of melanoma-associated antigen 1 in Chinese normal donors and hepatoma patients].
Wang LP; Chen HS; Mei MH; Qin LL; Cong X; Fei R; Xu J; Wei L
Zhonghua Gan Zang Bing Za Zhi; 2004 Mar; 12(3):151-5. PubMed ID: 15059299
[TBL] [Abstract][Full Text] [Related]
23. [Melanoma antigen-3 expression in human hepatocellular carcinoma].
Cai S; Zhao H; Leng X; Cheng J; Gong S; Peng J; Cong X; Wang Y; Rui J; Hui Y; Du R; Chen W
Zhonghua Wai Ke Za Zhi; 2000 Sep; 38(9):693-6. PubMed ID: 11832142
[TBL] [Abstract][Full Text] [Related]
24. Identification of immunogenic human melanoma antigens in a polyvalent melanoma vaccine.
Bystryn JC; Henn M; Li J; Shroba S
Cancer Res; 1992 Nov; 52(21):5948-53. PubMed ID: 1382848
[TBL] [Abstract][Full Text] [Related]
25. Frequent cytolytic T-cell responses to peptide MAGE-A10(254-262) in melanoma.
Valmori D; Dutoit V; Rubio-Godoy V; Chambaz C; Liénard D; Guillaume P; Romero P; Cerottini JC; Rimoldi D
Cancer Res; 2001 Jan; 61(2):509-12. PubMed ID: 11212242
[TBL] [Abstract][Full Text] [Related]
26. Identification of a new MAGE gene with tumor-specific expression by representational difference analysis.
Lucas S; De Smet C; Arden KC; Viars CS; Lethé B; Lurquin C; Boon T
Cancer Res; 1998 Feb; 58(4):743-52. PubMed ID: 9485030
[TBL] [Abstract][Full Text] [Related]
27. Functions of Anti-MAGE T-cells induced in melanoma patients under different vaccination modalities.
Connerotte T; Van Pel A; Godelaine D; Tartour E; Schuler-Thurner B; Lucas S; Thielemans K; Schuler G; Coulie PG
Cancer Res; 2008 May; 68(10):3931-40. PubMed ID: 18483279
[TBL] [Abstract][Full Text] [Related]
28. MAGE-1 expression threshold for the lysis of melanoma cell lines by a specific cytotoxic T lymphocyte.
Lethé B; van der Bruggen P; Brasseur F; Boon T
Melanoma Res; 1997 Aug; 7 Suppl 2():S83-8. PubMed ID: 9578421
[TBL] [Abstract][Full Text] [Related]
29. The immune response to disialoganglioside GD3 vaccination in normal dogs: a melanoma surface antigen vaccine.
Milner RJ; Salute M; Crawford C; Abbot JR; Farese J
Vet Immunol Immunopathol; 2006 Dec; 114(3-4):273-84. PubMed ID: 17027091
[TBL] [Abstract][Full Text] [Related]
30. Increased immunogenicity of tumor vaccines complexed with anti-Gal: studies in knockout mice for alpha1,3galactosyltransferase.
LaTemple DC; Abrams JT; Zhang SY; Galili U
Cancer Res; 1999 Jul; 59(14):3417-23. PubMed ID: 10416604
[TBL] [Abstract][Full Text] [Related]
31. Polyvalent melanoma cell vaccine induces delayed-type hypersensitivity and in vitro cellular immune response.
Barth A; Hoon DS; Foshag LJ; Nizze JA; Famatiga E; Okun E; Morton DL
Cancer Res; 1994 Jul; 54(13):3342-5. PubMed ID: 8012946
[TBL] [Abstract][Full Text] [Related]
32. The anti-tumor immune response induced by a combination of MAGE-3/MAGE-n-derived peptides.
Zhang XM; Zhang YF; Huang Y; Qu P; Ma B; Si SY; Li ZS; Li WX; Li X; Ge W; Hu PZ; Sui YF
Oncol Rep; 2008 Jul; 20(1):245-52. PubMed ID: 18575744
[TBL] [Abstract][Full Text] [Related]
33. Cloning and in vitro expression of a melanoma-associated antigen immunogenic in patients with melanoma.
Hayashibe K; Mishima Y; Ferrone S
J Immunol; 1991 Aug; 147(3):1098-104. PubMed ID: 1861072
[TBL] [Abstract][Full Text] [Related]
34. Identification and intracellular location of MAGE-3 gene product.
Kocher T; Schultz-Thater E; Gudat F; Schaefer C; Casorati G; Juretic A; Willimann T; Harder F; Heberer M; Spagnoli GC
Cancer Res; 1995 Jun; 55(11):2236-9. PubMed ID: 7757970
[TBL] [Abstract][Full Text] [Related]
35. Induction of antibodies to a tumor-associated antigen by immunization with a whole melanoma cell vaccine.
Euhus DM; Gupta RK; Morton DL
Cancer Immunol Immunother; 1989; 29(4):247-54. PubMed ID: 2752392
[TBL] [Abstract][Full Text] [Related]
36. Antibody responses to melanoma/melanocyte autoantigens in melanoma patients.
Huang SK; Okamoto T; Morton DL; Hoon DS
J Invest Dermatol; 1998 Oct; 111(4):662-7. PubMed ID: 9764850
[TBL] [Abstract][Full Text] [Related]
37. Identification of MAGE-1 and MAGE-4 proteins in spermatogonia and primary spermatocytes of testis.
Takahashi K; Shichijo S; Noguchi M; Hirohata M; Itoh K
Cancer Res; 1995 Aug; 55(16):3478-82. PubMed ID: 7627949
[TBL] [Abstract][Full Text] [Related]
38. Melanoma-associated antigen genes - an update.
Sang M; Wang L; Ding C; Zhou X; Wang B; Wang L; Lian Y; Shan B
Cancer Lett; 2011 Mar; 302(2):85-90. PubMed ID: 21093980
[TBL] [Abstract][Full Text] [Related]
39. Preparation and characterization of a polyvalent human melanoma antigen vaccine.
Bystryn JC; Jacobsen S; Harris M; Roses D; Speyer J; Levin M
J Biol Response Mod; 1986 Jun; 5(3):211-24. PubMed ID: 3723138
[TBL] [Abstract][Full Text] [Related]
40. Oncofetal antigen: a tumor-associated fetal antigen immunogenic in man.
Irie RF; Giuliano AE; Morton DL
J Natl Cancer Inst; 1979 Aug; 63(2):367-73. PubMed ID: 88539
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
